El-fatatry BM, et al. - In 40 patients with stage III colorectal cancer who completed 12 cycles of FOLFOX-4 regimen from November 2014 to May 2016, researchers assessed the role of metformin in oxaliplatin-induced peripheral neuropathy. Mean serum levels of malondialdehyde and neurotensin in metformin arm after the 6th and the 12th cycles were significantly lower. The results obtained from this randomized, controlled study indicate that metformin might be a promising drug in protecting patients with colorectal cancer against oxaliplatin-induced chronic peripheral sensory neuropathy.